Daniel Brox co-authored this post with Pratap Khedkar.
Access COVID-19 resources
As the world continues to monitor the spread of COVID-19, industries of all kinds have little choice but to change on the spot: Educational institutions are quickly transitioning their lessons online and dine-in restaurants are joining the delivery service industry. As measures like lockdowns and social distancing continue to be enforced amid the public health crisis, pharma needs to figure out what that means for the traditional rep-centric model. Putting a stop to in-person physician promotions would reduce traffic across sites of care (for locations that haven’t already restricted access), thereby lowering the spread of disease to healthcare workers, patients and the reps themselves. It’s the responsible thing to do but enforcing a work-from-home mandate—even temporarily—will be challenging. Big disruptions like these are sure to affect everyday business, but they also hold opportunities to rethink existing approaches and try out new ideas.
sales rep engagement,
pharma commercial model,
Earlier this year, experts agreed that telehealth was poised to become mainstream in 2020. Spurred by broad access through smartphones and supported by health plans across the U.S., telehealth finally has the financial reimbursement and regulatory guidelines to enable patients and physicians to connect online. But now, COVID-19 has come on the scene. With the outbreak of the coronavirus in China and its rapid spread around the world, private companies and governments have encouraged people to quarantine themselves if they believe that they may have the virus. But how do patients know if they have it? If they suspect that they do have it, how can they access care in a way that doesn’t expose others? And if patients have health questions unrelated to coronavirus, wouldn’t they prefer to stay away from clinics and hospitals to decrease their risk of exposure?
digital care delivery